|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||2.7500 - 2.9000|
|52 Week Range||1.4800 - 4.5000|
|Beta (3Y Monthly)||3.06|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HENDERSON NV / ACCESSWIRE / April 11, 2019 / With the market off to its best first quarter over the past 2 decades and the cannabis industry being one of the hottest in the market, now is an ideal time ...
There are a large number of publicly traded marijuana companies, with the biggest ones being located in Canada -- as Canada is the largest market where marijuana has been fully legalized, notes Ben Reynolds, editor of Sure Dividend in a special report on the best opportunities in the cannabis space.
OTCQX: EMHTF), a licensed producer of cannabis products for medical and recreational purposes, announced today that executives of the company will participate in multiple upcoming investment conferences.
CBD -- which is simply shorthand for cannabidiol -- is a non-psychoactive component of cannabis plants, explains Timothy Lutts, editor of Cabot Marijuana Investor.
OTCQX: EMHTF) today announced that its Québec facility, Verdélite, has received its Standard Processing License from Health Canada. This license means that, in addition to Verdélite’s right to cultivate and sell cannabis flowers, it can now extract, manufacture, synthesize, test and sell next-generation cannabis products and will position Verdélite to launch these products in conjunction with the expected legalization of a broader spectrum of cannabis products in Canada in October 2019.
How Medical Marijuana Stocks Performed on April 4(Continued from Prior Part)Medical marijuana stocks The cannabis sector saw some weakness on April 4. The ETFMG Alternate Harvest ETF (MJ) saw a negative price action of 0.11%. Charlotte’s Web
Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, public sentiment toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of influence.Additionally, marijuana stocks represent a viable economic channel that can help bridge the gap for many states' financial issues. For instance, green-friendly Colorado enjoys significant tax revenues from their botanical industry. I don't see this trend changing for the worse anytime soon, as awareness and popularity is only increasing.Of course, cannabis isn't without its controversies. Primarily, the federal government classifies marijuana as a Schedule I drug, putting it on par with hardcore narcotics like cocaine. Thus, no matter how liberal some states become toward their agricultural ambitions, the specter of federal oversight and crackdowns keeps many entrepreneurs and businesses away.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, we have one critical exception to the rule: marijuana stocks that specialize in medicinal and therapeutic benefits. For one thing, medical cannabis mitigates the stereotypical image of potheads and general no-gooders. Plus, people experiment with pharmaceuticals all the time. Why not allow these same patients the choice for natural alternatives?More critically for marijuana stocks, the medicinal aspect offers the best chance for international acceptance. Currently, very few jurisdictions allow recreational weed. Given the abundance of traditional and conservative nations, a green world is unlikely. But as Thailand and South Korea demonstrated, medical cannabis is a much easier sell. * 7 Biometric Stocks to Watch as AI Rises As a result, you want exposure not just to marijuana stocks, but also to the therapeutic element. Here are 10 names to consider: Medical Marijuana Stocks: AbbVie (ABBV)Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:ABBV) isn't the first name you think about. One of the healthcare sector's blue chips, ABBV stock has soared on its vast therapeutic pipeline. We're talking mainstream solutions for common ailments and diseases like arthritis and plaque psoriasis.Still, AbbVie maintains some botanical credibility with its Marinol therapy. A synthetic cannabis-based drug, Marinol addresses chemotherapy-related side effects, such as vomiting or nausea. In addition, it helps restore appetite among AIDS patients.Of course, you should note that Marinol isn't among AbbVie's top-selling products. Therefore, you're only getting limited exposure to cannabis with ABBV stock. But based on the extreme volatility of marijuana stocks, that isn't such a bad gig. Emerald Health Therapeutics (EMHTF)Source: Shutterstock Not that I would know, but growing cannabis allegedly isn't rocket science. With the right conditions, the right equipment and a reasonable car, anyone can grow their stash. But cultivating the plant so that it addresses specific ailments and symptoms? That takes real effort, which is where Emerald Health Therapeutics (OTCMKTS:EMHTF) comes in.Rather than just pumping out the green stuff, Emerald deliberately seeks out the strains most effective in addressing patients' needs. The company provides a wide selection of strains, which range in weight, tetrahydrocannabinol (THC) content, and cannabidiol (CBD) strength. Their impressive portfolio should lift EMHTF stock over the long run, as interest in CBD products accelerates. * The Elite 8 Stocks to Buy for Massive Outperformance More importantly, the markets share the same opinion. On year-to-date basis, EMHTF stock is up nearly 70%. While all cannabis stocks suffer volatility risk, Emerald's concentration on medicinal weed should help mitigate downside pressure. Aurora Cannabis (ACB)Source: Shutterstock I've spent a lot of time discussing Aurora Cannabis (NYSE:ACB), and I don't mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market.A key factor in my bullishness for Aurora is their management team. In my view, they're making smart decisions through their acquisitive strategy. Rather than merely focusing on outright capacity, they're looking out over the horizon. Aurora's buyout of Whistler Medical Marijuana gave the organization significant leverage in medical cannabis due to Whistler's extensive genetics bank.Furthermore, ACB stock is a strong performer. Since the January opener, shares have skyrocketed roughly 70%. While it's likely to cool off, the inevitable correction should be only temporary. Among marijuana stocks, Aurora is exceptionally well-positioned for sustainable growth. Cronos Group (CRON)Source: Shutterstock One of the top names among major marijuana stocks, Cronos Group (NASDAQ:CRON) naturally attracts a lot of attention. This time, though, they're attracting the wrong kind.Prior to its earnings report for the fourth quarter, I worried about the company's revenue target. Hit or exceed it, and management can stave off criticism. But fall short, and CRON stock could crumble. They missed the sales target -- quite badly, too -- and shares naturally reacted poorly.But speculators looking for a discounted price may want to put CRON stock back on their radar. Since the beginning of March, Cronos has shed over 16%. However, the magnitude of volatility has declined noticeably in the past few days. * 10 Tech Stocks That Transformed Their Business Plus, Cronos has international legitimacy among medicinally focused cannabis stocks. Featuring partnerships and joint ventures across five continents, the company is ahead of the game. CannTrust (CTST)Source: Shutterstock In business -- even the green kind -- you can't get ahead of yourself. So while lucrative opportunities exist in the international sector, CannTrust (NYSE:CTST) remains firmly committed to winning its native Canadian market.At the same time, CannTrust can't afford to ignore the rest of the world. Although Canada becoming the first G7 nation to legalize recreational weed generated headlines, our northern neighbors alone can't support this burgeoning industry. Therefore, management has focused on the growth and capacity narrative to compete effectively at home and, later, abroad.To achieve the second leg of this journey, CannTrust teamed up with Denmark's Stenocare to distribute medical-cannabis products in that country. It also inked a partnership with an Australian firm for similar distribution arrangements. While it's not the most common name among marijuana stocks, CTST stock provides a risky, but viable, opportunity. Innovative Industrial Properties (IIPR)Source: Shutterstock Most marijuana stocks focus on the industry's front face; namely, production. As I mentioned earlier, marijuana isn't that difficult to grow. So long as you have the green light legally, the physical barrier to entry is relatively short.But the real challenge, though, is finding a consistent source of financing. This is where Innovative Industrial Properties (NYSE:IIPR) lends a helping hand. Despite momentum toward legalization, several financial institutions shy away from cannabis ventures. Innovative Industrial plugs the gap, offering critical capital through its leaseback business model. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos Thanks to the company's tremendous utility, IIPR stock has lit up the markets. Shares are currently up 66% YTD. Technically, IIPR may have gotten a bit overheated. That said, I wouldn't get too greedy looking for the perfect entry point. Innovative Industrial levers a proven business model that is only increasing in relevancy. Terra Tech (TRTC)Source: Shutterstock Everyone recognizes cannabis stocks for two things: their incredible potential and their equally incredible volatility. Unfortunately, stakeholders of medical-cannabis producer Terra Tech (OTCMKTS:TRTC) find themselves in the latter category. Over the trailing year, TRTC stock is down around 60%.And the bad news doesn't end there. Unlike many other marijuana stocks, Terra Tech has had trouble generating top-line growth. In its most recent earnings report for the fourth quarter, the company reported $6.92 million in sales. This badly underperformed against the year-ago level, when Terra Tech generated revenue of $11 million.So why take a bet on TRTC stock? First, its vertically integrated organization may facilitate significant efficiencies as political momentum increases. Second, I dig their leadership team. The head execs are experts in finance, which should prove beneficial in properly navigating TRTC across choppy waters. Charlotte's Web (CWBHF)Source: Shutterstock When most people look at Charlotte's Web (OTCMKTS:CWBHF), they're thinking that they missed the boat. After all, CWBHF stock has jumped almost 113% since the beginning of this year. From the opening price of April, Charlotte's Web shares gained a ridiculous 16%.As much as I love marijuana stocks, I'm fairly certain that this cannabis firm is due for a pullback. But once that occurs, I wouldn't waste too much time squabbling over the granularity. Instead, I'd consider what our own Matt McCall had to say. Thanks to the popularity of CBD, Charlotte's Web's CBD-based products could be distributed across mainstream retail channels. * 7 Reasons Americans Should Embrace Socialism Unquestionably, such an event would launch CWBHF stock into the stratosphere. Moreover, because most CBD products contain no trace of THC, they don't fall under severe federal guidelines. Therefore, don't get too greedy looking for an ideal price point when CWBHF corrects. Cannabis Science (CBIS)Source: Shutterstock On paper, Cannabis Science (OTCMKTS:CBIS) represents the next evolution among cannabis stocks: pharmaceutical firms that devote their time and research exclusively toward medical marijuana. Not only that, this is a much-needed development that could lift CBIS stock, as well as the entire botanical industry.For decades, people unquestionably trusted the mainstream healthcare and pharmaceutical network. However, the rapidly escalating opioid crisis has proven that well-intentioned medical professionals can lever a tragic impact. One of the underlying causes of this crisis is the addictiveness of prescribed medicines.Organizations like Cannabis Science can potentially mitigate this situation with naturally sourced therapies free of psychoactive side-effects. That's the allure for CBIS stock. However, shares trade for less than 3 cents a pop, so this is only for the risk-tolerant. GW Pharmaceuticals (GWPRF)Source: Shutterstock On surface level, GW Pharmaceuticals (OTCMKTS:GWPRF) brings a lot of positives to the table. As pioneers among medicinally-concentrated marijuana stocks, they lever substantial credibility. Their Sativex drug for addressing symptoms associated with multiple sclerosis achieved better-than-expected results. This only encourages other companies to pursue cannabis-based therapies for many other diseases.That's the good news. The not-so-pleasant side of the coin, though, is market performance. While no one mistakes cannabis stocks as stable investment platforms, GWPRF stock is rough for even hardened botanical veterans. In December of last year, shares fell off a cliff before rebounding back toward low-earth orbit. * 7 Biometric Stocks to Watch as AI Rises So is GWPRF stock worth a look now? Although I like how the company has stabilized, I don't care for its low volume. But GW Pharmaceuticals is a penny stock with underappreciated talents. If you have the nerve and the patience, it's worth your consideration.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 10 Medical Marijuana Stocks to Cure Your Portfolio appeared first on InvestorPlace.
OTCQX: EMHTF) has signed a letter of intent to supply cannabis to the Société Québécoise du Cannabis (SQDC), Quebec's sole legal distributor of recreational cannabis. Under the agreement, Emerald will supply cannabis to the SQDC from its Québec-based Saint-Eustache facility, Verdélite, as well as from its 50%-owned joint venture, Pure Sunfarms, in Delta, BC. Emerald will fulfill its first supply order in Q2 2019. “Québec’s population of 8.4 million is a sizable market and we are pleased to be able to offer locally-grown, quality cannabis products to the adult-use consumers throughout the province,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald.
OTCQX: EMHTF) today announced that its 50%-owned joint venture, Pure Sunfarms, has exercised its option to acquire from Village Farms International, Inc. (“Village Farms”) a second 1.1 million square foot (25 acre) greenhouse (“Delta 2”) adjacent to Pure Sunfarms’ existing 1.1 million square foot cannabis operation (“Delta 3”) in Delta, BC. Pure Sunfarms expects to reach its annualized full production run-rate of approximately 75,000 kilograms by mid-year at Delta 3 and expects to double its overall production on completion of the conversion of Delta 2. Emerald has also entered into an agreement with Pure Sunfarms to purchase 25% of its aggregate cannabis production from Delta 3 and Delta 2 in 2020, 2021 and 2022.
OTCQX: EMHTF) has fulfilled its first purchase order of cannabis from Yukon Liquor Corporation, signed a sales agreement with Alberta Gaming, Liquor and Cannabis (AGLC), and become officially registered by the Saskatchewan Liquor and Gaming Authority (SLGA) to supply cannabis to the Saskatchewan market. “We are pleased to provide our Emerald-branded cannabis products to the adult-use markets in Alberta, Saskatchewan and the Yukon,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald.
OTCQX:EMHTF) today announced that it has established an at-the-market equity program (“ATM Program”) that allows the Company to issue common shares from treasury (“Common Shares”) having an aggregate gross sales price of up to $39 million to the public from time to time, at the Company’s discretion, at the prevailing market price when issued on the TSX Venture Exchange (“TSXV”) or on any other marketplace for the Common Shares in Canada. The ATM Program is effective until the earlier of April 13, 2021 or completion of the sale of the maximum amount of shares thereunder and will be activated from time to time at the Company’s discretion if and when required based on the Company’s working capital requirements and capital expenditures and relative cost of other funding options.
HENDERSON, NV / ACCESSWIRE / March 20, 2019 / With cannabis in the news and investors becoming more and more hungry for the next big winner in the industry, we decided to highlight a couple that could ...
OTCQX: EMHTF) applauds the Government of Canada for proposing to amend the excise tax calculation for cannabis in the federal budget announced yesterday. The implementation of the proposed revision announced in the federal budget would result in the calculation of the excise duty of ingestible cannabis and hemp products being based on the quantity of THC in the products, as opposed to the current tax set in relation to the product volume.
CORAL GABLES, FL / ACCESSWIRE / March 19, 2019 / One of the longest-running ways to reach the top of the marijuana stock market has been for companies to invest in growing cannabis. Taking that into consideration, there are companies that are seeing impressive gains as a result of their focus being the improvement of products for consumers in the cannabis market. Leafbuyer Technologies Inc (OTC:LBUY), Auxly Cannabis Group Inc (OTCQX:CBWTF), Emerald Health Therapeutics Inc (EMHTF), and HEXO Corp (NYSE American: HEXO, TSX: HEXO) represent 4 marijuana stocks looking strong on Tuesday.
OTCQX:EMHTF) announced today that Allan Rewak has been appointed Vice President, Communications and Stakeholder Relations, effective April 15, 2019. Prior to joining Emerald, Mr. Rewak was the Executive Director at the Cannabis Council of Canada (C3), Canada’s national industry association for cannabis, cultivators and processors. For his work, the Financial Post named him “One of the 20 Power Players Setting Down Roots in the Cannabis Industry”.
OTCQX:EMHTF) has fulfilled its first purchase order of cannabis from Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”). “As we scale up production in our wholly-owned, premium indoor growing facility, Verdélite, and our large-scale, state-of-the-art joint venture greenhouse operation, Pure Sunfarms, we are consistently meeting our supply commitments of Emerald-branded adult-use cannabis in British Columbia and Newfoundland Labrador, and we are now prepared to provide the same service to the Ontario Cannabis Retail Corporation and other provinces,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. Currently, Emerald’s cannabis supply is provided primarily through its 88,000 sq. ft. Verdélite indoor facility in Saint Eustache, Quebec, and through Pure Sunfarms, its 50%-owned 1.1 million sq. ft. greenhouse facility in Delta, British Columbia.
OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ -- OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...
Cannabis sales have been soaring since legalization in Canada but there's a lot more to come as the industry continues to change. Here are some of the hottest cannabis stocks right now that are positioning themselves to take advantage of the fast-growing retail market. Westleaf has been making a name for itself in the industry as it looks to become a dominant force in the retail market.
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / It's quite astounding that the marijuana stock market continues to receive so much attention despite the nascent nature of the cannabis industry. Having said that, the cannabis industry has seen a boom in excitement this past year as a result of lawmakers pushing for legislation in support of marijuana legalization. Global Consortium Inc (OTC:GCGX), Aphria Inc (APHA), Emerald Health Therapeutics Inc (EMHTF), and Innovative Industrial Properties Inc (IIPR) are 4 marijuana stocks heating up on Monday.
OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), received from Health Canada its seventh amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 206,000 square feet of growing area in the fourth and final quadrant of the greenhouse brings Pure Sunfarms’ total licensed cannabis production area to approximately 1.03 million sq. ft. in 16 grow rooms. “Pure Sunfarms is now licensed across all its growing areas and we congratulate their team for this significant accomplishment,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “With Emerald’s 50% stake in one of the largest fully operational cannabis production facilities in the world, we expect to realize significant economic value from Pure Sunfarms.
OTCQX:EMHTF) today announced that its joint venture partner’s, (Emerald Health Bioceuticals or “EHB”), Endo Bliss, won Taste For Life’s 2019 Essentials Supplement Award, which recognizes the most outstanding natural supplements in health and wellness in the U.S. Emerald will launch the Endo product line in Canada in 2019 through its joint venture, Emerald Health Naturals (“EHN”), which secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (“ECS”), but which does not contain cannabis.
Why Jim Cramer Likes Canopy Growth(Continued from Prior Part)Recurring themeJim Cramer has mentioned that alcoholic beverage companies are at risk due to growth in the cannabis sector (MJ).Jefferies echoed Cramer’s viewOn February 25, another
CORAL GABLES, FL / ACCESSWIRE / February 25, 2019 / The marijuana stock market has been incredibly active over the last few months with companies in the cannabis industry reaping the benefits of all the excitement. There are several factors that have resulted in the current state of the cannabis industry, the first of which relating to legislation put forth by progressives to legalize marijuana. Second of all, whereas companies in different industries rarely collaborate, cannabis companies have worked with companies across a variety of sectors to share the benefits of cannabis products with consumers, no matter the field.
Jefferies Initiates Coverage of CGC, TRST, ACB, OGRMF, and MoreJefferies initiates coverage on cannabisJust last week, we saw Seaport Global initiate coverage on some of the big cannabis players in the industry. Early this morning, yet another firm
CORAL GABLES, FL / ACCESSWIRE / February 21, 2019 / The 2019 year has already shown a significant amount of upward momentum for the marijuana stock market. A key reason for this tidal shift of positive energy is due to the fact that companies throughout the industry are progressing because many states in the U.S., as well as Canada, have passed legislation in favor of legalizing cannabis. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Emerald Health Therapeutics Inc (EMHTF) (TSX-VEMH), CannTrust Holdings Inc (OTC PINK: CNTTF), and KushCo Holdings Inc (KSHB) are 4 pot stocks that could test this week's highs.